A. Lexmond (Groningen, Netherlands), A. Mathioudakis (Manchester, United Kingdom), T. Greulich (Marburg, Germany), F. Lavorini (FIRENZE, Italy)
Evaluation of delivered dose and treatment time of several mesh nebulizers under in vitro simulated use L. Slator (Chichester, United Kingdom)
| |
Optimizing inhalation technique with web-based videos in obstructive lung diseases T. Mueller (Aachen, Germany)
| |
Pressurized Metered Dose Inhaler (pMDI) Delivery to Infants via Valved Holding Chamber (VHC) with Facemask: Not All VHCs Perform the Same A. Bracey (Gloucester, United Kingdom)
| |
Predictors of continuous positive airway pressure adherence in obstructive sleep apnea syndrome V. Leoni (Magnago, Italy)
| |
Effect of breath-actuated mechanism on the emitted particle characteristics and lung deposition of a fixed combination drug A. Farkas (Budapest, Hungary)
| |
Patients with underuse and overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhalation medication K. Koehorst-Ter Huurne (Enschede, Netherlands)
| |
Ease of use of inhalers and its impact on treatment adherence and control of asthma. An observational study E. Barbero Herranz (madrid, Spain)
| |
Delivery of Respimat Soft Mist inhaler (SMI) from a Valved Holding Chamber (VHC) V. Kushnarev (London, ON, Canada)
| |
The EDUCA (Elderly and Device Use in Chronic Asthma) multicentre Italian study on the assessment of errors and satisfaction in using the inhalers in elderly asthmatics: Preliminary results. S. Terraneo (Arosio, Italy)
| |
Effect of CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP,Formoterol Fumarate:FF,Glycopyrronium Bromide:GB) on Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRINITY study M. Scuri (PARMA, PR, Italy)
| |
Systemic bioavailability (BA) and pharmacodynamics (PD) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) or a novel breath-triggered inhaler (BTI) P. Dalvi (CAMBRIDGE, United Kingdom)
| |
Novel nebulisation of budesonide as add-on treatment in uncontrolled asthmatics M. Main (Chippenham, United Kingdom)
| |
Demonstration of therapeutic equivalence between Salmeterol/fluticasone Easyhaler and Seretide Diskus S. Lähelmä (Kuopio, Finland)
| |
Evaluating inhalation technique among COPD patients comparing 4 different methods A. Løkke (Højbjerg, Denmark)
| |
Assessment of Pulmonary Deposition between two formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/125 mcg R. Julliet (Mumbai (Maharashtra), India)
| |
Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg R. Julliet (Mumbai (Maharashtra), India)
| |
IN-VITRO AEROSOL DEPOSITION OF VALVED HOLDING CHAMBERS FOR CHILDREN WITH BUDESONIDE pMDI N. Buchmann (Gräfelfing, Germany)
| |
Electronic monitoring devices in clinical trials – a doddle to use? I. Adejumo (Nottingham, United Kingdom)
| |